Evidence map›Paper›PMID 31892958›Full record

ArticleMobile DNA2020

LINE-1 ORF2p expression is nearly imperceptible in human cancers.

Daniel Ardeljan, Xuya Wang, Mehrnoosh Oghbaie, Martin S Taylor, David Husband, Vikram Deshpande, Jared P Steranka, Mikhail Gorbounov, Wan Rou Yang, Brandon Sie and 9 more

Open access · goldAbstract read
In one paragraph

Article in Mobile DNA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
11.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Ultrasensitive Enzyme-Free Detection of Proteins on Magnetic Beads.Journal of the American Chemical Society · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Cancer cells subvert the primate-specific KRAB zinc finger protein ZNF93 to control APOBEC3B.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  15. A pan-cancer atlas of therapeutic T cell targets.bioRxiv : the preprint server for biology · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

Daniel Ardeljan *1McKusick Nathans Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
Xuya Wang *3Institute for Systems Genetics, Department of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, NY 10016 USA.
Mehrnoosh Oghbaie *4Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY 10065 USA.
Martin S Taylor2Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
David Husband2Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
Vikram Deshpande5Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114 USA.
Jared P Steranka2Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
Mikhail Gorbounov2Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
Wan Rou Yang2Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
Brandon Sie2Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
H Benjamin Larman2Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
Hua Jiang4Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY 10065 USA.
Kelly R Molloy6Laboratory of Mass Spectrometry and Gaseous Ion Chemistry, The Rockefeller University, New York, NY 10065 USA.
Ilya Altukhov7Moscow Institute of Physics and Technology, Dolgoprudny, 141701 Russia.
Zhi Li3Institute for Systems Genetics, Department of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, NY 10016 USA.
Wilson McKerrow3Institute for Systems Genetics, Department of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, NY 10016 USA.
David Fenyö3Institute for Systems Genetics, Department of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, NY 10016 USA.
Kathleen H Burns1McKusick Nathans Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
John LaCava4Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY 10065 USA.ORCID 0000-0002-6307-7713
Johns Hopkins University · USInstitute for Systems Biology · USRockefeller University · USHarvard University · USMoscow Institute of Physics and Technology · RUUniversity Medical Center Groningen · NL

Funding

Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
TR&D Project 4. The Imaging Stage: Multiscale Spatiotemporal Modeling of Macromolecular Systems in Cellular NeighborhoodsP41GM109824 · NIGMS · ROCKEFELLER UNIVERSITY · PI ROUT, MICHAEL P · 2014 to 2023
$18.8M
TRAINING IN AREAS FUNDAMENTAL TO CANCER RESEARCHT32CA009110 · NCI · JOHNS HOPKINS UNIVERSITY · PI MATUNIS, MICHAEL J., WEERARATNA, ASHANI T · 1985 to 2025
$13.1M
Training CoreP50GM107632 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BOEKE, JEF D · 2013 to 2017
$10.0M
Proteogenomic Data Analysis for Cancer Systems Biology and Clinical TranslationU24CA210972 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DING, LI, FENYO, DAVID · 2016 to 2020
$3.3M
Opportunities for Pathology Trainees in Cancer ResearchT32CA193145 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANDERS, ROBERT A., EBERHART, CHARLES G · 2015 to 2025
$2.6M
Demonstrating interactome-level connections between Alzheimer disease, LINE-1 retrotransposons, and cellular senescenceR01GM126170 · NIGMS · ROCKEFELLER UNIVERSITY · PI LACAVA, JOHN · 2018 to 2021
$2.4M
Expression and Impact of Interspersed RepeatsR01GM130680 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI BURNS, KATHLEEN H · 2019 to 2022
$1.4M
LINE-1 genotoxicity and cytotoxicity and its relevance to cancerF30CA221175 · NCI · JOHNS HOPKINS UNIVERSITY · PI ARDELJAN, DANIEL · 2017 to 2020
$150k
NCATS NIH HHS UL1 TR001866NCI NIH HHS F30 CA221175NCI NIH HHS T32 CA009110NCI NIH HHS T32 CA193145NCI NIH HHS U24 CA210972NIGMS NIH HHS P41 GM109824NIGMS NIH HHS P50 GM107632NIGMS NIH HHS R01 GM126170NIGMS NIH HHS R01 GM130680
6 · The paper itself

Abstract

backgroundLong interspersed element-1 (LINE-1, L1) is the major driver of mobile DNA activity in modern humans. When expressed, LINE-1 loci produce bicistronic transcripts encoding two proteins essential for retrotransposition, ORF1p and ORF2p. Many types of human cancers are characterized by L1 promoter hypomethylation, L1 transcription, L1 ORF1p protein expression, and somatic L1 retrotransposition. ORF2p encodes the endonuclease and reverse transcriptase activities required for L1 retrotransposition. Its expression is poorly characterized in human tissues and cell lines.

resultsWe report mass spectrometry-based tumor proteome profiling studies wherein ORF2p eludes detection. To test whether ORF2p could be detected with specific reagents, we developed and validated five rabbit monoclonal antibodies with immunoreactivity for specific epitopes on the protein. These reagents readily detect ectopic ORF2p expressed from bicistronic L1 constructs. However, endogenous ORF2p is not detected in human tumor samples or cell lines by western blot, immunoprecipitation, or immunohistochemistry despite high levels of ORF1p expression. Moreover, we report endogenous ORF1p-associated interactomes, affinity isolated from colorectal cancers, wherein we similarly fail to detect ORF2p. These samples include primary tumors harboring hundreds of somatically acquired L1 insertions. The new data are available via ProteomeXchange with identifier PXD013743.

conclusionsAlthough somatic retrotransposition provides unequivocal genetic evidence for the expression of ORF2p in human cancers, we are unable to directly measure its presence using several standard methods. Experimental systems have previously indicated an unequal stoichiometry between ORF1p and ORF2p, but in vivo, the expression of these two proteins may be more strikingly uncoupled. These findings are consistent with observations that ORF2p is not tolerable for cell growth.

Identifiers

PMID31892958
PMCPMC6937734
OpenAlexW3003405284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.